Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Angiogenesis-VEGF
- Angiogenesis-VEGF-C/D
- VEGF and VEGFR tyrosine kinase
- Strategies to inhibit VEGFR signaling
- MuMAb VEGF A4.6.1
- RhuMAb VEGF-Avastin
- Blocking Ab differ from other agents
- Anti-VEGF Ab prevents VEGF/VEGFR interaction
- Potential effects of inhibiting VEGF
- Anti-angiogenesis 'normalises' tumour vasculature
- Anti-VEGF Ab modifies tumor vasculature
- VEGF inhibition can induce capillary regression
- Ranibizumab
- Pegaptanib
- 'Metronomic' anti-angiogenic chemotherapy
- Preclinical models
- Potential effects of anti-VEGF therapy
- Anti-VEGFR2 mAb
- Treatment of human xenograft tumors with DC101
- VEGFR-2 blockade
- VEGFR-2 block leads to increase in tumor hypoxia
- Anti-VEGFR-2 mAb and gemcitabine
- VEGFR-2 Ab IMC-1121b
- Structure and properties of VEGF trap
- Angiogenesis inhibitors in clinical trials
- Conclusions (1)
- Conclusions (2)
- Inhibitors of lymphangiogenesis
- Tumor lymphangiogenesis and metastasis
- VEGF-C/D trap prevents VEGFR-3 signaling
- VEGF-C/D trap prevents lymph vessels growth
- Inhibition of lymphangiogenesis with VEGFR-3-Fc
- Blocking metastasis to lymph nodes
- Model of lymphatic metastasis
- Model of prevention of lymphatic metastasis
- Proteolytic processing of VEGF-C/D
- VEGF in hematogenous and lymphatic spread
- Antagonist monoclonal Abs to VEGFR-3
- Soluble receptors (traps) and antagonist antibodies
- Antagonist monoclonal antibodies to VEGFR-3
- Mode of action of antagonist mAbs to RTKs
- Functional properties of alpha-VEGFR-3 mAbs
- Dermal lymphatic regeneration model in mouse
- Systemic alpha-VEGFR-3 treatment
- Angio- and lymphangiogenesis blocking
- Alpha-VEGFR-3 inhibits growth of carcinomas
- Alpha-VEGFR-3 inhibits metastasis of carcinoma
- VEGF-C induces hypertrophy of lymphatic vessels
- Alpha-VEGFR-3 inhibits lymph vessels hypertrophy
- Alpha-VEGFR-3 reduces metastasis to lymph
- The role of VEGFR-3 in inflammation
- Expansion of the lymphatic network
- Prevention of lymphatic hyperplasia
- Alpha-VEGFR-3 modulates adaptive immunity
- VEGF-C, VEGFR-3 and inflammation (1)
- VEGF-C, VEGFR-3 and inflammation (2)
- Rejection of renal transplants
- Conclusions (3)
Topics Covered
- Antagonist monoclonal antibodies to VEGFR-3
- Mode of action of antagonist monoclonal antibodies
- Functional properties of antagonist antibodies to VEGFR-3
- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis
- Inhibition of pathological vessel growth in the cornea
- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors
- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3
- Role of VEGFR-3 in normal and pathological immune response
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Alitalo, K. and Pytowski, B. (2007, October 1). VEGF inhibitors for anti-angiogenic therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/SSHQ8214.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Kari Alitalo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Bronislaw Pytowski has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.